Jaguar inks deal with Glenmark to produce animal diarrhea drugs

Jaguar Animal Health ($JAGX) has inked a four-year deal with India's Glenmark Pharmaceuticals to manufacture and supply crofelemer for use in treating diarrhea in pets.

Crofelemer is the API in Jaguar's lead prescription drug Canalevia, which is designed to be used for treating various forms of watery diarrhea in dogs. The San Francisco-based company is also working on formulations of Canalevia for use in cats and horses.

Glenmark currently manufactures Fulyzaq, which is a human-specific formulation of crofelemer used to treat noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy, the company said in a release. It was approved by the FDA in 2012.

Jaguar CEO Lisa Conte

"Given Glenmark's long-term experience in the manufacture of crofelemer, we expect this relationship to allow us to bring Canalevia to market in the most efficient, rapid and cost-effective manner possible," Lisa Conte, Jaguar's president and CEO, said in a statement.

Jaguar, having filed its New Animal Drug Application in August, is still awaiting word from the FDA on Canalevia.

Last month, Glenmark lost a bid before India's top court to clear existing stocks of sitagliptin as it awaits a ruling over whether it can sell copies of Januvia and Janumet, Merck's ($MRK) innovative version of the Type 2 diabetes drug.

- read the Jaguar release